Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Cole Robinson

Interventional Pain Medicine Richfield, UT Medical Doctor

NPI 1871799528 CMS profile 986339

860 N Main St Ste B, Richfield, UT 84701

Open in the dashboard

General payments

$5,399

129 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cole Robinson of Richfield, UT is reported in the CMS Open Payments database as having received $5,399 across 129 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 58th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $298 22
2024 General $2,287 25
2023 General $235 23
2022 General $86 6
2021 General $314 17
2020 General $1,004 16
2019 General $1,175 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cole Robinson
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Cole Robinson were reported at $298. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Cole Robinson Interventional Pain Medicine median Middle half National median
2019 $1,175 $684 $216–$2,079 $163
2020 $1,004 $382 $122–$1,109 $114
2021 $314 $552 $167–$1,554 $132
2022 $86 $605 $187–$1,924 $149
2023 $235 $671 $195–$1,915 $160
2024 $2,287 $684 $206–$1,837 $164
2025 $298 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $5,224 119 payments
  2. Relievant Medsystems, Inc. $64 4 payments
  3. Nevro Corp. $45 3 payments
  4. Stryker Corporation $34 1 payment
  5. Pfizer Inc. $16 1 payment
  6. Abbott Laboratories $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $3,149 12 payments
  2. Food and Beverage $2,250 117 payments
Products named General payments · program years 2019–2025
  1. SPECTRA WAVEWRITER $1,759 14 payments
  2. GENERAL PAIN MANAGEMENT $439 23 payments
  3. General - Pain Management General - Pain Management_NMD $164 11 payments
  4. GENERAL - PAIN MANAGEMENT Pain Management $132 8 payments
  5. Intracept Intracept Access Instruments (Gen 3)_NMOD $61 2 payments
  6. General - Therapies $54 4 payments
  7. CoverEdge 32 $48 9 payments
  8. Senza Spinal Cord Stimulation System $45 3 payments
  9. SUPERION $44 1 payment
  10. Intracept Pain $42 2 payments
  11. Other $214 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,345

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$38,682

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

34%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 131 $12,861
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 232 $6,138
Buprenorphine Generic 14 $3,774
Gabapentin Generic 239 $3,752
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 167 $3,340
Fentanyl Generic 18 $1,818
Morphine Sulfate Er Morphine Sulfate Brand 58 $1,281
Pregabalin Generic 74 $1,170
Celecoxib Generic 49 $904
Tramadol Hcl Generic 79 $647

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$295,410

Of which drugs: $2,098

Medicare patients

560

Average age 74

Services billed

4,378

322 women, 238 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 74%
High blood pressure 70%
Depression 30%
Diabetes 29%
Chronic kidney disease 25%
Ischemic heart disease 18%
Heart failure 17%
Osteoporosis 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 199 1,471 $1,063
Injection, fentanyl citrate, 0.1 mg J3010 Office 19 30 $22
Injection, midazolam hydrochloride, per 1 mg J2250 Office 20 49 $5

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

129 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record